(untitled) - Cree, BA C; Bennett, J L; Kim, H J
Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (NMOmentum). A double-blind, randomised placebo-controlled phase 2/3 trial. Lancet 2019: doi: 10.1016/S0140-6736(19)31817-3